Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-07-07

Schrödinger, Inc.

Schrödinger sells computational molecular discovery software and uses the same platform to generate collaboration, milestone, royalty, and equity upside from drug discovery programs.

ai biotech enterprise healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From Scientific Tool to Discovery Operating Layer

The upside case rests on becoming the trusted system of record for computational discovery while turning more molecular work into ratable hosted revenue. If that works, value creation comes more from workflow ownership and revenue quality than from a binary biotech pipeline outcome.

Analysis

Thesis

Schrödinger can become a higher-quality discovery software compounder if hosted delivery, Bunsen, and workflow trust features convert rising AI-driven molecular work into recurring paid throughput while partnerships keep most biology upside off balance sheet.

Last Economy Alignment

Cheaper cognition should push more discovery work through Schrödinger’s physics engine and workflow layer, and its usage-led pricing is less exposed to seat compression. The risk is that generic agents or customer-built stacks own the interface and reduce Schrödinger to a back-end scientific utility.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.9x (from 5 most recent analyses)

Reasoning

This is mainly a quality-of-revenue rerating with real growth, not a moonshot pipeline call. If hosted licensing makes revenue more recurring, Bunsen lifts paid workflow throughput, and collaboration upside is monetized without rebuilding a heavy internal biotech model, the business can look more like a durable discovery operating layer than a niche scientific tool.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is value capture, not relevance. Schrödinger must prove that hosted delivery restores margin quality and that Bunsen keeps paid workflow ownership inside its stack rather than helping generic agents commoditize the interface. Customer concentration, cloud dependence, and therapeutics timing add noise, but the strategic question is whether more AI activity strengthens Schrödinger’s tollbooth or bypasses it.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On June 29, 2026, Lilly’s acquisition of Ajax closed and Schrödinger disclosed an approximately 57 cash payment plus additional milestone rights.
No company-reported Bunsen launch or customer-activation update arrived by July 7, so the summer 2026 AI checkpoint remains open.
No new financing event was disclosed in the last 7-10 days; the near-term balance-sheet picture improved mainly because of the Ajax cash receipt.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.50

They control a scientific workflow layer and simulation engine that drug teams already use, so cheaper AI can send more paid work through their system instead of replacing it. The risk is that generic agents become the front door and push Schrödinger into a back-end role unless hosted workflows become the trusted record customers do not want to leave.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$20.88

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research